Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.

Key facts

Study ID

NCT00003761

Run by

Dana-Farber Cancer Institute

People needed

20

Starts

1999-03-03

Expected to finish

2001-10-19

Last updated by the study team

2017-02-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Boston Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.